Rising Stars in Malignant Hematology Conference 2025

Saturday, October 18th , 2025  • Toronto, ON

Conference Objectives

The 2025 Rising Stars in Malignant Hematology Conference will serve a foundational role in helping early-in-practice hematologists gain meaningful insight into patient and disease management for hematologic malignancies. This event is geared towards the early-in-practice clinician and will include didactic lectures, complex case discussions, and panel Q&A sessions.

Scientific Steering Committee

The scientific steering committee for the 2025 Rising Stars in Malignant Hematology Conference includes Dr. Peter Anglin and Dr. Alissa Visram.

Dr. Alissa Visram

Dr. Peter Anglin

Register Today: Spots Are Limited!

Only 40 spots, including limited travel grants, are available for this one-of-a-kind conference and we encourage you to register early.

If you are able to join us, kindly RSVP by registering to the conference using the link below. Registrations will close on August 31st, 2025, or when the conference reaches capacity. As space is limited, we encourage you to RSVP at your earliest convenience if you plan to attend.

Conference Agenda

The 2025 Rising Stars in Malignant Hematology Conference will serve a foundational role in helping early-in-practice hematologists gain meaningful insight into patient and disease management for hematologic malignancies.

Time

Topic

Speaker

8:30 - 8:45 AM

Welcome & Opening Remarks

Alissa Visram

8:45 AM–9:15 AM

Sponsored Symposium

TBD

9:15 AM–9:45 AM

Bispecific antibody therapy practical management in 2025

Richard Leblanc

9:45 AM–10:15 AM

CAR T-cell therapy long-term toxicity management in 2025

Christine Chen

10:15 AM–10:45 AM

Sequencing in rrMM in 2025

Irwindeep Sandhu

10:45 AM–11:00 AM

Networking Break

ALL

11:00 AM–11:30 AM

Approach to Hodgkin’s lymphoma in 2025

Mary Margaret Keating

11:30 AM–12:15 PM

Panel Discussion

Full Faculty

12:15 PM–1:00 PM

LUNCH

ALL

1:00 PM–1:30 PM

Sponsored Symposium

TBD

1:30 PM- 2:00 PM

Updates on the management of MPN in 2025

Vikas Gupta

2:00 PM- 2:30 PM

CLL management in 2025 (front-line vs relapse)

Carolyn Owen

2:30 PM- 2:45 PM

Networking Break

ALL

2:45 PM- 3:15 PM

Non-intensive AML therapy: frontline and first relapse

Julie Bergeron

3:15 PM- 3:45 PM

Relapsed aggressive B-cell lymphoma: A 2025 overview

Michael Chu

3:45 PM- 4:00 PM

Closing Remarks & Adjournment

Peter Anglin

Our Sponsors
Founding Sponsors
Silver Sponsors
Forus Logo
Bristol-Myers_Squibb_logo_(2020).svg
Bronze Sponsors
Screenshot 2024-11-19 at 3.44.42 PM
GleadKite Logo

Subscribe To Canadian Hematology Today

Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.

The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians and researchers across Canada. It features peer-reviewed articles that present robust clinical perspectives and practical insights into disease management.

About Catalytic Health

Founded in 2009, Catalytic Health is one of Canada’s largest medical education agencies and reaches over 50,000 Canadian clinicians a year with its educational programs, services and platforms. Catalytic Health is also the largest independent medical publisher in Canada, one of the largest scientific conference providers, and a leader in innovative events and services for the Life Sciences industry. Learn more about Catalytic Health.

© 2025 All Rights Reserved.

Dr. Alissa Visram is a hematologist at the Ottawa Hospital and an assistant professor within the Department of Medicine. She completed her hematology training at Dalhousie University in Nova Scotia, and her subspecialty clinical and research fellowship in plasma cell disorders at Mayo Clinic. Dr. Visram holds a Masters in Public Health and Epidemiology from Harvard University. She joined faculty in Ottawa in September of 2021 as a clinician investigator. Her clinical research is centered on understanding and improving health outcomes of patients with plasma cell disorders and developing cost-effective and efficacious immunotherapies for patients with multiple myeloma.

Dr. Peter Anglin’s clinical focus remains in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. He has also developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients. He continues to serve in an advisory capacity to a number of pharmaceutical and health-related organizations. He remains the medical director of CarePath, a cancer navigation and support service supporting Cancer Care Ontario and Ontario cancer patients.